flyadeal starts daily flights to Tabuk

Updated 21 April 2018

flyadeal starts daily flights to Tabuk

flyadeal, Saudi Arabia’s low-cost airline, has announced that it will be operating flights daily to Tabuk from May 3. The northern city is the latest addition to the airline’s growing network, which now comprises seven key destinations in the Kingdom.
The launch of the new route has been made possible by the recent arrival of “Al-Qaws,” flyadeal’s sixth new Airbus A320 aircraft.
Ticket prices start from SR108 ($29) between Tabuk and Jeddah and SR198 ($53) between Tabuk and Riyadh, if booked sufficiently early.
“The city of Tabuk is currently the center of significant developmental activity with the NEOM project at its forefront. The new project will boost the economy of the Kingdom, and also have a positive impact on its aviation sector,” said Con Korfiatis, CEO of flyadeal.


J-Clinic study identifies powerful new drug

Updated 26 February 2020

J-Clinic study identifies powerful new drug

A powerful new antibiotic compound has been identified by researchers at MIT using a machine-learning algorithm. The drug killed many of the world’s most problematic disease-causing bacteria in laboratory tests, including some strains that are resistant to all known antibiotics. It also cleared infections in two different mouse models.

The computer model, which can screen more than a 100 million chemical compounds in a matter of days, is designed to pick out potential antibiotics that kill bacteria using different mechanisms than those of existing drugs. 

Regina Barzilay and James Collins, who are faculty co-leads for MIT’s Abdul Latif Jameel Clinic for Machine Learning in Health (J-Clinic), are the senior authors of the study, which appears in Cell. The first author of the paper is Jonathan Stokes, a post-doc at MIT and the Broad Institute of MIT and Harvard.

J-Clinic is a key part of the MIT Quest for Intelligence and focuses on developing machine-learning technologies to revolutionize the prevention, detection, and treatment of disease.

In their new study, the researchers also identified several other promising antibiotic candidates, which they plan to test further. They believe the model could also be used to design new drugs, based on what it has learned about chemical structures that enable drugs to kill bacteria.

“The machine-learning model can explore, in silico, large chemical spaces that can be prohibitively expensive for traditional experimental approaches,” said Barzilay, the Delta Electronics professor of electrical engineering and computer science in MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL).

Over the past few decades, very few new antibiotics have been developed, and most of those newly approved antibiotics are slightly different variants of existing drugs. Current methods for screening new antibiotics are often prohibitively costly, require a significant time investment, and are usually limited to a narrow spectrum of chemical diversity.

“We’re facing a growing crisis around antibiotic resistance, and this situation is being generated by both an increasing number of pathogens becoming resistant to existing antibiotics, and an anemic pipeline in the biotech and pharmaceutical industries for new antibiotics,” Collins said.

“The world is in desperate need of new antibiotics to combat dangerous diseases, so it is hugely encouraging that the team at J-Clinic at MIT, has helped make a breakthrough in finding a genuinely new one using machine learning,” said Fady Jameel, Community Jameel president, international. “For decades, Community Jameel has been committed to supporting research that can help improve people’s lives. Combatting the risk from antibiotic-resistant infections, like tuberculosis, could have a profound impact on us all.”

The research was funded and made possible by a number of supporters including the Abdul Latif Jameel Clinic for Machine Learning in Health.